Roche expects to bring its obesity drug candidates to market by 2028, with projected sales of over 3 billion Swiss francs. Roche aims to cut drug development costs by 20% and reduce time to Phase 3 ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

Discovering new drugs is an expensive proposition. From 2012 to 2022, adjusting for inflation, spending on pharmaceutical research and development increased by almost half to roughly $250bn, according ...

Pharmaceutical giant Roche may have made profits more than a hundred times what it cost the company to bring a rare-disease drug to the Indian market, The Times of India reported on April 28. The drug ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...